An observational study in Valve Heart Disease, Aortic Stenosis and Aortic Regurgitation, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by The Cleveland Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Heart Valve Diseases with a site in United States — 39 open to participants now, 50 under way, none of them phase 3. Heart Valve Diseases · United States.
Among the 111 studies in Heart Valve Diseases with a site in United States, this one is the 25th largest by planned enrollment of the 45 observational ones that give a count, is one of 9 that started in 2019, is one of 45 observational ones, reaches primary completion later than 26 of the 49 other live ones, and was the 60th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →39 of the 111 studies in Heart Valve Diseases with a site in United States are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in United States
Ages 18+
Edwards Lifesciences · Sites in United States
Ages 18+
Medtronic Cardiovascular · Sites in United States
Ages 18+
Laplace Interventional, Inc · Sites in United States
Ages 18–90
VDyne, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 207 across the 66 interventional studies, 353 across the 45 observational. Of the 54 that completed or were terminated, 30 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 111 have an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
The Cleveland Clinic has 4 studies filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
13 of the studies in Heart Valve Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06965725Endeavor HealthPaired-Ring Mitral Annuloplasty Ring Sizing Device | 2026-11 |
| NCT04843371Tulane UniversityPPG to Predict Ejection Fraction and Other Echographic Data in the General Population | 2026-12 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT07224906HemoCept Inc.Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization | 2027-01 |
| NCT06077201Vanderbilt University Medical CenterHome-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions | 2027-02-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies in Heart Valve Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the various 2D and 3D methods of valvular heart disease quantification (Doppler, PISA, VCA, volumetric method) and strain with cardiac magnetic resonance (CMR) measurements of left and right ventricular systolic function strain and myocardial fibrosis assessment.
The objective of this study is to compare the accuracy of 3D TTE to 2D TTE in assessing the severity of valvular heart disease in patients with aortic stenosis, aortic regurgitation, and mitral valve regurgitation by comparing this to the reference standard of cardiac magnetic resonance (CMR) in subjects with different etiologies and mechanisms of valvular lesions and to the integrative method of valvular lesion grading as recommended by inter-societal guidelines. Another objective is to assess prevalence of focal and diffuse myocardial fibrosis as assessed by CMR in patients with aortic stenosis, aortic regurgitation and mitral regurgitation. In addition, the investigators aim to determine whether severity of myocardial fibrosis predicts onset of symptoms, referral for valve surgery and adverse ventricular remodeling. The investigators also aim to look at patients who will be undergoing CRT implant to predict their response to therapy.
At baseline, the Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire will be completed. A 6-12 month follow-up is required and will include an abbreviated non-contrast research cardiac MRI and subject questionnaires.
Other follow-up will include using electronic medical records and the Social Security Death Index database for outcomes such as death, hospitalization for heart failure, mitral or aortic valve interventions and cardiovascular death.
Select patients will be asked to undergo a supine bicycle exercise stress MRI at enrollment. Approximately 40 subjects will be included in this substudy.
Additional exclusion criteria for this substudy:
During the exercise stress MRI, patients will be asked to cycle on a supine bike that will be mounted on the MRI platform. During this test, a caregiver will be present. An electrocardiogram (ECG) will be used to obtain tracings of cardiac activity. Respirations, blood pressure, and heart rate are also monitored during exercise. The test is continued until peak exercise level or target heart rate is achieved. As soon as the exercise portion is complete, MRI images will be acquired. When the test is complete, patients will be monitored until ECG, heart rate, and breathing have returned to baseline. Patients will be assessed for symptoms such as chest pain, dyspnea, leg pain, dizziness, or fatigue and may be given medications or instructed to stop the test early as necessary.
Patients with suspected chronic AS, AR, MR or heart failure with reduced ejection fraction being evaluated for CRT implantation referred for clinically indicated CMR and echocardiography by their cardiologists.. CMR and echocardiography will be clinically indicated in this study group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam.
Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography
Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam.
Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography
Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam.
Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography
Patients who meet clinical guideline criteria for CRT implantation with EF \< 40%
Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography
CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
Doppler, PISA, VCA, volumetric method as performed during echocardiography
Change in MRI Quantified LVEDVi
10% Change from Baseline - units of measure cc/m2
Time frame: 6 months
Change in MRI Quantified LVESVi
15% Change from Baseline - units of measure cc/m2
Time frame: 6 months
Change in MRI Quantified LV Strain
5% Change from Baseline
Time frame: 6 months
Change in MRI LVEF
5% Change from Baseline
Time frame: 6 Months
Change in Kansas City Cardiomyopathy Questionnaire Answers
Change in quality of life related to heart failure symptoms.
Time frame: 6 Months
Change in Physical Activity Questionnaire Answers
Change in physical activity level due to heart failure symptoms.
Time frame: 6 Months
All-cause mortality
number of patients expired
Time frame: 6 Months
Development of class I or IIa indication for valve surgery
The recommended indications for surgery include: development of symptoms, LV dysfunction (LV end-systolic diameter ≥45 mm or LV ejection fraction ≤60%), and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary artery pressure \>50 mm Hg at rest).
Time frame: 6 Months
Accuracy of echocardiography as compared with MRI
Comparison of MRI measurements based on standard of care echocardiography.
Time frame: 6 Months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2019 (actual). Primary completion is estimated for Dec 2027, 100 months after the start.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 100 months is above that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.